Is Cancer Research a Good Journal? Impact, Scope, and Fit
Cancer Research is a broad AACR venue for consequential basic, translational, and clinical cancer research. Use its current scope and evidence burden to test fit.
Journal fit
See whether this paper looks realistic for Cancer Research.
Run the Free Readiness Scan with Cancer Research as your target journal and see whether this paper looks like a realistic submission.
Cancer Research at a glance
Key metrics to place the journal before deciding whether it fits your manuscript and career goals.
What makes this journal worth targeting
- Cancer Research's scope and readership determine whether the journal is a useful target.
- Scope specificity matters more than headline metrics for most manuscript decisions.
- Selectivity at this journal means fit and framing determine most outcomes.
When to look elsewhere
- When your paper sits at the edge of the journal's stated scope, borderline fit rarely improves after submission.
- If timeline matters: Cancer Research takes Varies by manuscript. A faster-turnaround journal may suit a grant or job deadline better.
- If open access is required by your funder, verify the journal's OA agreements before submitting.
How to read Cancer Research as a target
This page should help you decide whether Cancer Research belongs on the shortlist, not just whether it sounds impressive.
Question | Quick read |
|---|---|
Best for | Cancer Research is published by the American Association for Cancer Research and reports original studies,. |
Editors prioritize | Cancer mechanism with clear relevance to tumor biology or therapy |
Think twice if | Cancer mechanism without clinical relevance or therapeutic potential |
Typical article types | Research Article, Brief Communication |
Quick answer: Cancer Research is a credible target for rigorous cancer biology with a broad, potentially generalizable conclusion. AACR's current 2026 metrics page lists a journal metric of 22.6. The more useful fit test is whether the paper advances cancer understanding across models or contexts, not whether it can be attached to an unsupported acceptance-rate estimate.
Evidence basis: We reviewed current official AACR journal, scope, and metrics materials on 2026-08-21. Official journal sources establish the published facts below. Manusights judgment applies them to manuscript fit; journal-level metrics cannot predict an individual decision.
The editorial distinction that matters is breadth. Cancer Research covers basic, translational, and clinical work across cancer biology, so the bar is not merely a technically sound study involving a tumor. The paper needs a cancer-research consequence that the intended readership can recognize.
Cancer Research at a Glance
Metric | Detail |
|---|---|
Current figure on AACR's 2026 metrics page | 22.6 |
Publisher | AACR (American Association for Cancer Research) |
Quartile | Q1 (Oncology) |
Format | Research Articles, Priority Communications |
Published acceptance rate | Not provided on the official page reviewed |
Access and charges | Verify the live AACR author page |
Key Strength | Broad basic cancer biology with conceptual depth |
How Cancer Research Compares to Peer Journals
Journal | Primary editorial center | When it may own the paper better |
|---|---|---|
Cancer Research | Broad cancer-research insight | The result travels beyond one model, tumor, or technique |
Cancer Cell | Highly consequential mechanistic cancer biology | The mechanism and evidence support a field-level claim |
Cancer Discovery | Major basic-to-clinical cancer advance | The discovery has unusually broad disease or therapeutic consequence |
Clinical Cancer Research | Explicit mechanism-to-clinic bridge | A patient, biomarker, therapeutic, or clinical decision owns the paper |
Oncogene | Focused cancer gene and pathway biology | A narrower molecular contribution is the honest center |
The AACR family structure matters for the decision, but copied impact-factor comparisons become stale quickly. Recheck each live journal page if metrics affect reporting or institutional requirements; choose the owner from scope, evidence, and audience.
What Cancer Research Editors Actually Select
The editorial filter is: does this paper advance how the broad cancer research community understands biology, not just document another finding in a specific tumor type?
Papers that do well typically:
- Make a conceptual point that generalizes beyond one tumor model or one pathway
- Are unmistakably about cancer - not generic molecular biology with tumor cells as the experimental system
- Deliver mechanism, not just phenotype or association
- Would be read by cancer researchers outside the exact disease niche
The manuscript-level risk is a technically strong paper about one tumor type or pathway whose consequence remains local. Test whether the work teaches a broader cancer-research audience something transferable rather than assigning it a hypothetical audience size.
Who should submit, and who should avoid Cancer Research
Submit if:
- Your paper makes a conceptual advance in cancer biology that matters beyond one narrow tumor or pathway niche
- The work is unmistakably cancer-first - removing the word "cancer" would collapse the manuscript
- The mechanism is explained, not just described - you have moved beyond phenotype and correlation
- Broad cancer researchers (not just your subfield) would genuinely want to read this paper
Think twice if:
- The paper is really molecular biology or immunology with tumor cells as the model system - a general biology or immunology journal may serve it better
- The contribution is descriptive - a new marker, a new association, a new dataset without a conceptual payoff
- The real audience is one narrow disease community - a disease-specific journal may give better visibility
- The work is strong enough for Cancer Cell or Cancer Discovery - do not undersubmit by defaulting to Cancer Research
Journal fit
See whether this paper looks realistic for Cancer Research.
Run the scan with Cancer Research as the target. Get a manuscript-specific fit signal before you commit.
Common decision questions
Is Cancer Research harder to get into than Oncogene?
Cancer Research generally demands broader cancer significance and conceptual depth, while Oncogene can fit a more focused gene-biology contribution. The official pages reviewed do not supply comparable manuscript-level acceptance rates, so route by scope and audience rather than a percentage.
Should I try Cancer Cell first?
If the mechanistic story would change how the cancer field thinks about a fundamental process, Cancer Cell may be worth evaluating. Cancer Research is not a consolation prize; it owns a broader cancer-research job. Compare the live scopes and the manuscript's actual contribution before selecting either.
Does Cancer Research publish computational or technology papers?
Yes, when the primary contribution is a cancer insight - not just a method demonstration. A new computational tool published in Cancer Research should reveal cancer biology, not just demonstrate the tool on cancer data.
How does the review process work?
AACR describes the journal's peer-review process and article routes in its current author materials. Timing varies by manuscript and reviewer availability, so use the live submission system rather than a copied range.
Bottom Line
Cancer Research is a broad AACR journal for consequential cancer research. If the paper teaches the cancer community something genuinely new and the audience extends beyond the immediate niche, it can be a strong target. If the clinical decision, narrow molecular pathway, or technical artifact owns the work, compare the neighboring venue whose readers and evidence standard fit that center better.
Before submitting, a Cancer Research scope and readiness check can help you assess whether the conceptual advance and evidence package match Cancer Research's editorial expectations.
Before you submit
A Cancer Research submission readiness check identifies the specific framing and scope issues that trigger desk rejection before you submit.
Use it after the manuscript's central claim and evidence package are stable. A readiness check can expose a mismatch, but it cannot supply the missing cross-model validation or broader cancer consequence on the authors' behalf.
Test whether the cancer insight travels
Cancer Research describes a broad basic, translational, and clinical cancer-research remit. The useful fit question is not whether the model involves cancer. It is whether the study teaches the field something that travels beyond one cell line, cohort, tumor subtype, or technology demonstration.
Manuscript center | Strong Cancer Research case | Better route when missing |
|---|---|---|
Mechanism | Perturbation and rescue evidence establish a cancer-relevant mechanism across appropriate models | A specialist molecular or disease-site journal if the mechanism is narrow |
Translational bridge | Biomarker, therapeutic, or resistance finding has human anchoring and a defined decision pathway | Clinical Cancer Research when the clinical bridge owns the paper |
Resource or method | The resource changes a general cancer-research capability and is validated against a meaningful benchmark | A methods or data journal when the artifact, not the cancer insight, is primary |
Tumor-specific discovery | The subtype reveals a principle with a credible boundary and wider consequence | A disease-focused oncology journal when local depth matters more than transfer |
Write the paper's “travels because” sentence. For example: “Although the cohort is restricted to [tumor], the study changes [broader decision] because [mechanism or validation].” If that sentence needs hype or omits the model boundary, the journal choice deserves another pass.
Evidence basis: The current AACR journal page, author instructions, and 2026 AACR metrics page support the scope, editorial criteria, and 22.6 metric used here. The table is Manusights synthesis, not an AACR acceptance model, and it cannot predict acceptance or an editorial outcome. Hold a mechanism paper if the central claim rests on one model, hold a translational claim if the human bridge is missing, and stop a resource pitch if the artifact has no general cancer-research use. Those failure signals are more actionable than an unofficial acceptance estimate.
- AACR Journals metrics (checked August 24, 2026).
Frequently asked questions
Yes. Cancer Research is an established AACR journal for cancer biology with a broad, generalizable conclusion. The current journal metric is context, not a prediction for one paper.
The official pages reviewed for this guide do not provide a current manuscript-level acceptance denominator. Test the paper against the journal's scope and evidence burden instead of using a third-party estimate.
Cancer Research has a broad basic and translational cancer remit. Cancer Cell emphasizes highly consequential mechanistic work. Compare the present contribution and audience rather than unsupported acceptance percentages.
Its remit includes basic, translational, and clinical cancer research. A study whose clinical decision pathway owns the paper may fit a more explicitly clinical oncology venue, so check the current AACR scope.
Cancer Research emphasizes cancer insight with broad reach; Clinical Cancer Research emphasizes an explicit mechanism-to-clinic bridge. Choose the journal whose reader job the evidence already supports.
Free guide
A ranked list cannot tell you where your own paper belongs.
The guide runs the last-ten-papers test, which is reading what a journal has actually published recently and asking whether your paper would sit comfortably beside it. Then you score each candidate 0 to 2 on fit, and let impact factor break ties rather than start the decision.
Final step
See whether this paper fits Cancer Research.
Run the Free Readiness Scan with Cancer Research as your target journal and get a manuscript-specific fit signal before you commit.
Target journal Cancer Research
Private API processing. Your manuscript is not used to train models.
See example reportsPut the guidance to work
Build a journal decision from more than one signal.
Use comparison data as a starting point, then confirm the live source that governs the actual submission decision.
Where to go next
Start here
Same journal, next question
- Cancer Research Submission Guide: Requirements & What Editors Want
- How to Avoid Desk Rejection at Cancer Research
- Cancer Research Review Time: What Authors Can Actually Expect
- Cancer Research Acceptance Rate: What Authors Can Use
- Cancer Research Impact Factor 2026: Ranking, Quartile & What It Means
- Cancer Research Cover Letter: What Editors Actually Need to See